Get the Stockscreener App
3.40
1.19%
0.04
Puma Biotechnology Inc stock is traded at $3.40, with a volume of 395.41K.
It is up +1.19% in the last 24 hours and up +0.00% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.36
Open:
$3.4
24h Volume:
395.41K
Relative Volume:
1.15
Market Cap:
$168.74M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
5.5738
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
+0.29%
1M Performance:
+0.00%
6M Performance:
+14.48%
1Y Performance:
-8.11%
1-Day Range:
$3.335
$3.415
1-Week Range:
$3.335
$3.63
52-Week Range:
$2.225
$4.13
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.40 | 168.27M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Is Puma Biotechnology Inc. a good long term investmentSkyrocketing returns - Jammu Links News
What drives Puma Biotechnology Inc. stock priceSignificant capital appreciation - Autocar Professional
Puma Biotechnology Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Does Puma Biotechnology Inc. stock pay reliable dividendsFree Access to Community - Newser
What analysts say about Puma Biotechnology Inc. stockTremendous gains - Jammu Links News
how puma biotechnology inc. stock performs during market volatilityFree Stock Selection - Newser
How Puma Biotechnology Inc. stock performs during market volatilityFree Stock Selection with 300% Return - Newser
Why Puma Biotechnology Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Puma Biotechnology Inc. stock price move sharplySteady Income Ideas - Newser
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma biotechnology CFO Nougues sells $33649 in stock By Investing.com - Investing.com South Africa
Puma biotechnology CFO Nougues sells $33649 in stock - Investing.com Australia
Puma biotechnology SVP Hunt sells $27624 in stock By Investing.com - Investing.com South Africa
Puma biotechnology SVP Hunt sells $27624 in stock - Investing.com Australia
Puma Biotechnology Executives Sell Shares Amid Ongoing Company Challenges - AInvest
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - Yahoo Finance
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Puma Biotechnology, Inc.(NasdaqGS: PBYI) dropped from Russell 2000 Growth Index - MarketScreener
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment (NASDAQ:PBYI) - Seeking Alpha
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - Nasdaq
Puma Biotechnology Updates Bylaws for Compliance - TipRanks
Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World
Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NOUGUES MAXIMO F | Chief Financial Officer |
Jul 08 '25 |
Sale |
3.53 |
5,587 |
19,739 |
208,164 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jul 09 '25 |
Sale |
3.54 |
3,935 |
13,910 |
204,229 |
| HUNT DOUGLAS M | See Remarks |
Jul 08 '25 |
Sale |
3.53 |
4,374 |
15,453 |
168,337 |
| HUNT DOUGLAS M | See Remarks |
Jul 09 '25 |
Sale |
3.54 |
3,443 |
12,171 |
164,894 |
| AUERBACH ALAN H | President and CEO |
Jul 08 '25 |
Sale |
3.53 |
25,592 |
90,417 |
7,202,481 |
| AUERBACH ALAN H | President and CEO |
Jul 09 '25 |
Sale |
3.54 |
21,580 |
76,285 |
7,180,901 |
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):